CME credit for this article is now expired. It appears here for informational purposes. Some of the material may have changed.
Premiere Date: October 20, 2013
CME Expiration Date: October 20, 2014
The goal of this activity is to present information on personalized medicine and how it may be used to guide the decision making process in psychiatry.
At the end of this article, readers should be able to:
1. Identify the factors that make up a patient’s physiological psychiatric profile.
2. Recognize the role of genetics, environment, and epigenetics in personal medicine.
3. Describe how clinical phenotype can be used to more clearly identify a diagnosis.
This continuing medical education activity is intended for psychiatrists, psychologists, primary care physicians, physician assistants, nurse practitioners, and other health care professionals who seek to improve their care for patients with mental health disorders.
CME Credit (Physicians): This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of CME Outfitters, LLC, and Psychiatric Times. CME Outfitters, LLC, is accredited by the ACCME to provide continuing medical education for physicians.
CME Outfitters designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note to Nurse Practitioners and Physician Assistants: AANPCP and AAPA accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer-review process.
The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr Ozomaro has received grant support from the National Institutes of Health/National Institute of Mental Health.
Dr Nemeroff is a consultant for Xhale, Takeda, SK Pharma, Lundbeck, Shire, Roche, Eli Lilly, and Allergan; has received grant/support from the National Institutes of Health, Agency for Healthcare Research and Quality; is a stock shareholder of CeNeRx BioPharma, PharmaNeuroBoost, Reevax Pharma, Xhale, and NovaDel Pharma; is or has been on the Board of Directors of American Foundation for Suicide Prevention (AFSP), Mt Cook Pharma (2010), NovaDel Pharma (2011), Skyland Trail, Gratitude America, and Anxiety and Depression Association of America (ADAA); sat on the Scientific Advisory Board for AFSP, CeNeRx BioPharma, National Alliance for Research on Schizophrenia and Depression, Xhale, PharmaNeuroBoost, ADAA, Skyland Trail, and AstraZeneca Pharmaceuticals (2009); holds a patent for method and devices for transdermal delivery of lithium (US 6,375,990B1) and for a method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2); and has equity or other financial interests in AstraZeneca Pharmaceuticals, PharmaNeuroBoost, CeNeRx BioPharma, NovaDel Pharma, Reevax Pharma, American Psychiatric Publishing, and Xhale.
Dr Wahlestedt is a consultant for OPKO Health as well as a co-founder of Epigenetix Inc and Itherapeutics Corp. He has received grant support from the National Institutes of Health.
Lloyd Sederer, MD (peer/content reviewer), reports that he receives grant support from the National Institute of Mental Health and the National Center for Complementary and Alternative Medicine.
Applicable Psychiatric Times staff have no disclosures to report.
Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, and the faculty do not endorse the use of any product outside of the FDA-labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity?
Call us at 877.CME.PROS(877.263.7767).
Dr Ozomaro is a Resident Physician, Jackson Memorial Medical Center, University of Miami Leonard M. Miller School of Medicine, Miami. Dr Nemeroff is Chairman of the Department of Psychiatry and Behavioral Sciences, Director of the Center of Aging, and Chief of Psychiatry at Jackson Memorial Hospital and at the University of Miami Hospital at the Leonard M. Miller School of Medicine. Dr Wahlestedt is Associate Dean for Therapeutic Innovation, Leonard M. Miller Professor, Director of the Center for Therapeutic Innovation, and Vice Chair of Research for the Department of Psychiatry and Behavioral Sciences at the University of Miami Leonard M. Miller School of Medicine.
1. Mehta R, Jain RK, Badve S. Personalized medicine: the road ahead. Clin Breast Cancer. 2011;11:20-26.
2. Pratt LA, Brody DJ, Gu Q. Antidepressant use in persons aged 12 and over: United States, 2005-2008. NCHS data brief, no 76. Hyattsville, MD: National Center for Health Statistics; 2011.
3. Trivedi MH, Rush AJ, Wisniewski SR, et al; STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28-40.
4. Nordentoft M, Mortensen PB, Pedersen CB. Absolute risk of suicide after first hospital contact in mental disorder. Arch Gen Psychiatry. 2011;68:1058-1064.
5. Ozomaro U, Wahlestedt C, Nemeroff CB. Personalized medicine in psychiatry: problems and promises. BMC Med. 2013;11:132.
6. Li D, Zhao H, Gelernter J. Strong protective effect of the aldehyde dehydrogenase gene (ALDH2) 504lys (*2) allele against alcoholism and alcohol-induced medical diseases in Asians. Hum Genet. 2012;131:725-737.
7. Zintzaras E, Stefanidis I, Santos M, Vidal F. Do alcohol-metabolizing enzyme gene polymorphisms increase the risk of alcoholism and alcoholic liver disease? Hepatology. 2006;43:352-361.
8. Cannon M, Jones PB, Murray RM. Obstetric complications and schizophrenia: historical and meta-analytic review. Am J Psychiatry. 2002;159:1080-1092.
9. McGuffin P, Asherson P, Own M, Farmer A. The strength of the genetic effect. Is there room for an environmental influence in the aetiology of schizophrenia? Br J Psychiatry. 1994;164:593-599.
10. Saveanu RV, Nemeroff CB. Etiology of depression: genetic and environmental factors. Psychiatr Clin North Am. 2012;35:51-71.
11. Nemeroff CB, Heim CM, Thase ME, et al. Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma [published correction appears in Proc Natl Acad Sci U S A. 2005;102:16530]. Proc Natl Acad Sci U S A. 2003;100:14293-14296.
12. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89-95.
13. Kapur S, Phillips AG, Insel TR. Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? Mol Psychiatry. 2012;17:1174-1179.
14. FDA permits marketing of first brain wave test to help assess children and teens for ADHD [press release]. Silver Spring, MD: US Food and Drug Administration; July 15, 2013.
15. Mathalon DH, Hoffman RE, Watson TD, et al. Neurophysiological distinction between schizophrenia and schizoaffective disorder. Front Hum Neurosci. 2010;3:70.
16. Bogdan R, Hyde LW, Hariri AR. A neurogenetics approach to understanding individual differences in brain, behavior, and risk for psychopathology. Mol Psychiatry. 2013;18:288-299.
17. Frodl T, Möller HJ, Meisenzahl E. Neuroimaging genetics: new perspectives in research on major depression? Acta Psychiatr Scand. 2008;118:363-372.
18. Grieve SM, Korgaonkar MS, Etkin A, et al. Brain imaging predictors and the international study to predict optimized treatment for depression: study protocol for a randomized control trial. Trials. 2013;14:224.
19. Brammer M. The role of neuroimaging in diagnosis and personalized medicine—current position and likely future directions. Dialogues Clin Neurosci. 2009;11:389-396.
20. Bühler M, Mann K. Alcohol and the human brain: a systematic review of different neuroimaging methods. Alcohol Clin Exp Res. 2011;35:1771-1793.
21. Höflich A, Savli M, Comasco E, et al. Neuropsychiatric deep brain stimulation for translational neuroimaging. Neuroimage. 2013;79:30-41.
22. Linden DE. The challenges and promise of neuroimaging in psychiatry. Neuron. 2012;73:8-22.